Literature DB >> 17056575

Involvement of TNF-like weak inducer of apoptosis in the pathogenesis of collagen-induced arthritis.

Koichi Kamata1, Seiji Kamijo, Atsuo Nakajima, Akemi Koyanagi, Hisashi Kurosawa, Hideo Yagita, Ko Okumura.   

Abstract

TNF-like weak inducer of apoptosis (TWEAK) is a type II membrane protein belonging to the TNF family that regulates apoptotic cell death, cellular proliferation, angiogenesis, and inflammation. However, the role of TWEAK in the pathogenesis of rheumatoid arthritis (RA) remains unclear. In this study, we have investigated the effect of neutralizing anti-TWEAK mAb on the development of collagen-induced arthritis (CIA), a well-established murine model of RA. Administration of anti-TWEAK mAb significantly ameliorated paw swelling, synovial hyperplasia, and infiltration of inflammatory cells. The levels of proinflammatory chemokines such as MCP-1 and MIP-2 in serum and knee joints were reduced by this treatment. Consistently, recombinant TWEAK enhanced the proliferation of MCP-1 and MIP-2 production by synovial cells from CIA mice in vitro. Histological examination also revealed that the treatment with anti-TWEAK mAb suppressed the development of small vessels in synovial tissues. These results indicated anti-inflammatory and antiangiogenic effects of the TWEAK blockade in CIA, which may be also beneficial for the treatment of RA.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17056575     DOI: 10.4049/jimmunol.177.9.6433

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  30 in total

1.  Fn14-TRAIL, a chimeric intercellular signal exchanger, attenuates experimental autoimmune encephalomyelitis.

Authors:  Marjaneh Razmara; Brendan Hilliard; Azadeh K Ziarani; Ramachandran Murali; Srikanth Yellayi; Mustafa Ghazanfar; Youhai H Chen; Mark L Tykocinski
Journal:  Am J Pathol       Date:  2009-01-15       Impact factor: 4.307

Review 2.  The TWEAK-Fn14 system as a potential drug target.

Authors:  Harald Wajant
Journal:  Br J Pharmacol       Date:  2013-10       Impact factor: 8.739

3.  TRAF2 and cIAP2 involve in TWEAK-induced MMP-9 production in fibroblast-like synoviocytes.

Authors:  Liping Xia; Hui Shen; Jing Lu; Weiguo Xiao
Journal:  Rheumatol Int       Date:  2011-01-13       Impact factor: 2.631

4.  Serum TWEAK as a biomarker for disease activity of systemic lupus erythematosus.

Authors:  Jung-Yoon Choe; Seong-Kyu Kim
Journal:  Inflamm Res       Date:  2016-02-26       Impact factor: 4.575

5.  Full-length, membrane-anchored TWEAK can function as a juxtacrine signaling molecule and activate the NF-kappaB pathway.

Authors:  Sharron A N Brown; Arundhati Ghosh; Jeffrey A Winkles
Journal:  J Biol Chem       Date:  2010-04-12       Impact factor: 5.157

6.  Fibroblast growth factor inducible (Fn14)-specific antibodies concomitantly display signaling pathway-specific agonistic and antagonistic activity.

Authors:  Steffen Salzmann; Axel Seher; Johannes Trebing; Daniela Weisenberger; Alevtina Rosenthal; Daniela Siegmund; Harald Wajant
Journal:  J Biol Chem       Date:  2013-03-26       Impact factor: 5.157

7.  The destruction evaluation in different foot joints: new ideas in collagen-induced arthritis rat model.

Authors:  Peng Zhang; Dong Han; Tingting Tang; Xiaoling Zhang; Kerong Dai
Journal:  Rheumatol Int       Date:  2008-11-04       Impact factor: 2.631

Review 8.  Role of the TWEAK/Fn14 pathway in autoimmune diseases.

Authors:  Wang-Dong Xu; Yi Zhao; Yi Liu
Journal:  Immunol Res       Date:  2016-02       Impact factor: 2.829

9.  The TWEAK-Fn14 system is a critical regulator of denervation-induced skeletal muscle atrophy in mice.

Authors:  Ashwani Mittal; Shephali Bhatnagar; Akhilesh Kumar; Estelle Lach-Trifilieff; Sandrine Wauters; Hong Li; Denys Y Makonchuk; David J Glass; Ashok Kumar
Journal:  J Cell Biol       Date:  2010-03-22       Impact factor: 10.539

10.  TWEAK and its receptor Fn14 in the synovium of patients with rheumatoid arthritis compared to psoriatic arthritis and its response to tumour necrosis factor blockade.

Authors:  A W R van Kuijk; C A Wijbrandts; M Vinkenoog; T S Zheng; K A Reedquist; P P Tak
Journal:  Ann Rheum Dis       Date:  2010-01       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.